Human Neutrophil Peptides 1-3 Are Useful Biomarkers in Patients with Active Ulcerative Colitis

被引:37
|
作者
Kanmura, Shuji [1 ]
Uto, Hirofumi [1 ]
Numata, Masatsugu [2 ]
Hashimoto, Shinichi [1 ]
Moriuchi, Akihiro [1 ]
Fujita, Hiroshi [1 ]
Oketani, Makoto [1 ]
Ido, Akio [1 ]
Kodama, Mayumi [3 ]
Ohi, Hidehisa [4 ]
Tsubouchi, Hirohito [1 ]
机构
[1] Kagoshima Univ, Grad Sch Med & Dent Sci, Kagoshima 890, Japan
[2] Kyoto Univ Hosp, Translat Res Ctr, Dept Expt Therapeut, Kyoto 606, Japan
[3] Miyazaki Univ, Fac Med, Dept Internal Med, Div Gastroenterol & Hematol, Miyazaki, Japan
[4] Imamura Hosp, Div Gastroenterol, Kagoshima, Japan
关键词
biomarkers; inflammatory bowel disease; ulcerative colitis; human neutrophil peptides 1-3; SELDI-TOF/MS; proteomics; INFLAMMATORY-BOWEL-DISEASE; COLORECTAL-CANCER; EPITHELIAL-CELLS; ALPHA-DEFENSINS; CROHNS-DISEASE; LEUKOCYTAPHERESIS; EXPRESSION; MARKERS; INTERLEUKIN-10; DISCOVERY;
D O I
10.1002/ibd.20854
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: A Specific useful biomarker for diagnosing ulcerative colitis (UC) has not yet been described. This Study employed proteomics to identify serum protein biomarkers for UC. Methods: Ninety-four blood samples were isolated from patients and controls (including 48 UC, 22 Crohn's disease [CD]. 5 colorectal cancer, and 6 infectious colitis patients and 13 healthy subjects). Set-Urn samples were analyzed using the SELDI-TOF/MS Protein-Chip system. After applying the samples to ProteinChip arrays, we assessed differences in the proteomes using Ciphergen ProteinChip software and identified candidate proteins, which were then characterized in immunoassays. Results: Preliminary analysis using the ProteinChip system revealed significant peak-intensity differences for 27 serum proteins between 11 patients with UC and 7 healthy Subjects. Among these proteins, 3 proteins (with mass/charge ratios of approximately 3400) were identified as human neutrophil peptides 1-3 (HNP 1-3). The presence of HNP 1-3 in the patient sera was confirmed using immunoassays. Enzyme-linked immunosorbent assays demonstrated that the mean plasma concentration of HNP 1-3 was significantly higher in patients with active UC (n = 28) than in patients whose UC was in remission (it = 20) or patients with CD (n = 22), infectious colitis, or healthy subjects, and tended to be higher than in patients with colon cancer. In addition, the plasma concentration of HNP 1-3 in patients that responded to corticosteroids-based therapy decreased after treatment, whereas it was not changed in nonresponders. Conclusions: HNP 1-3 is a novel biomarker that may be useful for diagnosing patients with active UC and predicting treatment outcomes.
引用
收藏
页码:909 / 917
页数:9
相关论文
共 50 条
  • [31] Peripheral blood T-lymphocyte subsets are potential biomarkers of disease severity and clinical outcomes in patients with ulcerative colitis: a retrospective study
    Geng, Bailu
    Ding, Xueli
    Li, Xiaoyu
    Liu, Hua
    Zhao, Wenjun
    Gong, Haihong
    Tian, Zibin
    Guo, Jing
    BMC GASTROENTEROLOGY, 2023, 23 (01)
  • [32] Fecal lactoferrin, myeloperoxidase and serum C-reactive are effective biomarkers in the assessment of disease activity and severity in patients with idiopathic ulcerative colitis
    Masoodi, Ibrahim
    Kochhar, Rakesh
    Dutta, Usha
    Vaishnavi, Chetana
    Prasad, Kaushal K.
    Vaiphei, Kim
    Kaur, Sukhminder
    Singh, Kartar
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 (11) : 1768 - 1774
  • [33] Optimal apheresis treatment volume for the efficacy and safety of leukocytapheresis with cellsorba in patients with active ulcerative colitis
    Fukunaga, Ken
    Kamikozuru, Koji
    Yokoyama, Yoko
    Hida, Nobuyuki
    Ohda, Yoshio
    Takeda, Naohisa
    Yoshida, Koji
    Iimuro, Masaki
    Kikuyama, Risa
    Kato, Kyoichi
    Nagase, Kazuko
    Nakamura, Shiro
    Miwa, Hiroto
    Matsumoto, Takayuki
    JOURNAL OF CLINICAL APHERESIS, 2011, 26 (06) : 326 - 331
  • [34] Active and passive smoking behaviour and cessation plans of patients with Crohn's disease and ulcerative colitis
    van der Heide, Frans
    Dijkstra, Arie
    Albersnagel, Frans A.
    Kleibeuker, Jan H.
    Dijkstra, Gerard
    JOURNAL OF CROHNS & COLITIS, 2010, 4 (02) : 125 - 131
  • [35] Tofacitinib in ulcerative Colitis - rapid Response in 1/3 of Patients
    Stallmach, A.
    GASTROENTEROLOGE, 2020, 15 (01): : 2 - 2
  • [36] Human neutrophil peptides 1, 2 and 3 (HNP 1-3): elevated serum levels in colorectal cancer and novel marker of lymphatic and hepatic metastasis
    Kemik, O.
    Kemik, A. S.
    Sumer, A.
    Begenik, H.
    Purisa, S.
    Tuzun, S.
    HUMAN & EXPERIMENTAL TOXICOLOGY, 2013, 32 (02) : 167 - 171
  • [37] Specific fungi associated with response to capsulized fecal microbiota transplantation in patients with active ulcerative colitis
    Chen, Qiongyun
    Fan, Yanyun
    Zhang, Bangzhou
    Yan, Changsheng
    Chen, Zhangran
    Wang, Lin
    Hu, Yiqun
    Huang, Qingwen
    Su, Jingling
    Ren, Jianlin
    Xu, Hongzhi
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2023, 12
  • [38] The Intra-Individual Variability of Faecal Calprotectin: A Prospective Study In Patients With Active Ulcerative Colitis
    Lasson, Anders
    Stotzer, Per-Ove
    Ohman, Lena
    Isaksson, Stefan
    Sapnara, Maria
    Strid, Hans
    JOURNAL OF CROHNS & COLITIS, 2015, 9 (01) : 26 - 32
  • [39] Presence and diagnosis of amebic infestation in Turkish patients with active ulcerative colitis
    Ozin, Yasemin
    Kilic, Mesut Zeki Yalin
    Nadir, Isilay
    Tayfur, Oyku
    Ertas, Arzu
    Ulker, Aysel
    Sahin, Burhan
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2009, 20 (05) : 545 - 547
  • [40] High intestinal and systemic levels of decoy receptor 3 (DcR3) and its ligand TL1A in active ulcerative colitis
    Bamias, Giorgos
    Kaltsa, Garyfallia
    Siakavellas, Spyros I.
    Papaxoinis, Kostis
    Zampeli, Evanthia
    Michopoulos, Spyros
    Zouboulis-Vafiadis, Irene
    Ladas, Spiros D.
    CLINICAL IMMUNOLOGY, 2010, 137 (02) : 242 - 249